Literature DB >> 10764809

Studies on the subsite specificity of rat nardilysin (N-arginine dibasic convertase).

K M Chow1, E Csuhai, M A Juliano, J St Pyrek, L Juliano, L B Hersh.   

Abstract

The subsite specificity of rat nardilysin was investigated using fluorogenic substrates of the type 2-aminobenzoyl-GGX(1)X(2)RKX(3)GQ-ethylenediamine-2,4- dinitrophenyl, where P(2), P(2)', and P(3) residues were varied. (The nomenclature of Schechter and Berger (Schechter, I., and Berger, A. (1967) Biochem. Biophys. Res. Commun. 27, 157-162) is used where cleavage of a peptide occurs between the P(1) and P(1)' residues, and adjacent residues are designated P(2), P(3), P(2)', P(3)', etc.) There was little effect on K(m) among different residues at any of these positions. In contrast, residues at each position affected k(cat), with P(2) residues having the greatest effect. The S(3), S(2), and S(2)' subsites differed in their amino acid preference. Tryptophan and serine, which produced poor substrates at the P(2) position, were among the best P(2)' residues. The specificity at P(3) was generally opposite that of P(2). Residues at P(2), and to a lesser extent at P(3), influenced the cleavage site. At the P(2) position, His, Phe, Tyr, Asn, or Trp produced cleavage at the amino side of the first basic residue. In contrast, a P(2) Ile or Val produced cleavage between the dibasic pair. Other residues produced intermediate effects. The pH dependence for substrate binding showed that the enzyme prefers to bind a protonated histidine. A comparison of the effect of arginine or lysine at the P(1)' or P(1) position showed that there is a tendency to cleave on the amino side of arginine and that this cleavage produces the highest k(cat) values.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764809     DOI: 10.1074/jbc.M909020199

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Towards a systems understanding of MHC class I and MHC class II antigen presentation.

Authors:  Jacques Neefjes; Marlieke L M Jongsma; Petra Paul; Oddmund Bakke
Journal:  Nat Rev Immunol       Date:  2011-11-11       Impact factor: 53.106

2.  The origin of proteasome-inhibitor resistant HLA class I peptidomes: a study with HLA-A*68:01.

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2011-10-03       Impact factor: 5.911

3.  Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes.

Authors:  Jan H Kessler; Selina Khan; Ulrike Seifert; Sylvie Le Gall; K Martin Chow; Annette Paschen; Sandra A Bres-Vloemans; Arnoud de Ru; Nadine van Montfoort; Kees L M C Franken; Willemien E Benckhuijsen; Jill M Brooks; Thorbald van Hall; Kallol Ray; Arend Mulder; Ilias I N Doxiadis; Paul F van Swieten; Hermen S Overkleeft; Annik Prat; Birgitta Tomkinson; Jacques Neefjes; Peter M Kloetzel; David W Rodgers; Louis B Hersh; Jan W Drijfhout; Peter A van Veelen; Ferry Ossendorp; Cornelis J M Melief
Journal:  Nat Immunol       Date:  2010-12-12       Impact factor: 25.606

4.  In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes.

Authors:  Yinxing Liu; Hanjun Guan; Tina L Beckett; Maria Aparecida Juliano; Luiz Juliano; Eun Suk Song; K Martin Chow; M Paul Murphy; Louis B Hersh
Journal:  Peptides       Date:  2007-09-29       Impact factor: 3.750

5.  The metalloendopeptidase nardilysin (NRDc) is potently inhibited by heparin-binding epidermal growth factor-like growth factor (HB-EGF).

Authors:  Véronique Hospital; Eiichiro Nishi; Michael Klagsbrun; Paul Cohen; Nabil G Seidah; Annik Prat
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

6.  Mammalian pitrilysin: substrate specificity and mitochondrial targeting.

Authors:  K Martin Chow; O Gakh; I C Payne; Maria Aparecida Juliano; Luiz Juliano; G Isaya; Louis B Hersh
Journal:  Biochemistry       Date:  2009-04-07       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.